Matches in Wikidata for { <http://www.wikidata.org/entity/Q104468242> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q104468242 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 14ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104468242 description "article scientifique publié en 2020" @default.
- Q104468242 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104468242 description "scientific article published on 14 December 2020" @default.
- Q104468242 description "wetenschappelijk artikel" @default.
- Q104468242 description "наукова стаття, опублікована 14 грудня 2020" @default.
- Q104468242 name "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 name "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 name "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 type Item @default.
- Q104468242 label "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 label "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 label "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 prefLabel "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 prefLabel "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 prefLabel "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 P1433 Q104468242-EBF6251D-AA6E-4A38-B4C8-44D01AF5759C @default.
- Q104468242 P1476 Q104468242-21400997-7B99-4F3F-9A5F-6DA6049D0D11 @default.
- Q104468242 P2093 Q104468242-177063E7-28CE-4340-A183-C0A21E1B6B06 @default.
- Q104468242 P2093 Q104468242-7EE9373A-88B6-4EF7-952E-1D4696D8D398 @default.
- Q104468242 P2093 Q104468242-9AB96F9E-8612-475A-88A9-78D2054FF8B0 @default.
- Q104468242 P2093 Q104468242-AB0D5840-86B6-451A-AE2D-692E8494325A @default.
- Q104468242 P2093 Q104468242-C352A008-EB6D-4B42-92DC-B6707D4F3297 @default.
- Q104468242 P2093 Q104468242-CE335003-39DD-4244-8888-A41CB44B84E6 @default.
- Q104468242 P2093 Q104468242-D32631F9-2CDB-4F2B-BE70-85F0D9ECF1D7 @default.
- Q104468242 P275 Q104468242-02255ac9-b3e1-4889-bb98-39c9e5e569ce @default.
- Q104468242 P304 Q104468242-F2196EE5-F6F3-40AF-AB2F-134D0C67B360 @default.
- Q104468242 P31 Q104468242-2F2B1DC8-6BEC-4DBD-93AB-BAA4F5622874 @default.
- Q104468242 P356 Q104468242-6A0FA9B4-2F4F-4527-BF7C-F8DAFEEFBAC3 @default.
- Q104468242 P433 Q104468242-C0D07815-D9F0-4EFB-99F7-77F1E805149B @default.
- Q104468242 P478 Q104468242-72FF497C-3759-46DA-AEBB-11D969CD4547 @default.
- Q104468242 P50 Q104468242-26FD28CF-5AEF-410A-AF2D-AAB7B9731E45 @default.
- Q104468242 P577 Q104468242-69801CF3-4E8E-4C2D-BF88-7718A15AEBCE @default.
- Q104468242 P6216 Q104468242-f4a67af2-fc9a-4524-aad8-c3ed6a95434d @default.
- Q104468242 P698 Q104468242-7A007A08-7E6E-4A36-A18D-EA8165C76C18 @default.
- Q104468242 P921 Q104468242-56FA3C68-31C7-466B-95CF-3607568F5F29 @default.
- Q104468242 P932 Q104468242-AC8812DF-CF56-4F68-B8C7-FA702D3E5CFB @default.
- Q104468242 P356 JOURNAL.PONE.0243729 @default.
- Q104468242 P698 33315881 @default.
- Q104468242 P1433 Q564954 @default.
- Q104468242 P1476 "Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis" @default.
- Q104468242 P2093 "Ayano Mori" @default.
- Q104468242 P2093 "Goh Tsuji" @default.
- Q104468242 P2093 "Miho Shibata" @default.
- Q104468242 P2093 "Miho Takahashi" @default.
- Q104468242 P2093 "Saori Hatachi" @default.
- Q104468242 P2093 "Soshi Takahashi" @default.
- Q104468242 P2093 "Toshiharu Saito" @default.
- Q104468242 P275 Q20007257 @default.
- Q104468242 P304 "e0243729" @default.
- Q104468242 P31 Q13442814 @default.
- Q104468242 P356 "10.1371/JOURNAL.PONE.0243729" @default.
- Q104468242 P433 "12" @default.
- Q104468242 P478 "15" @default.
- Q104468242 P50 Q104468241 @default.
- Q104468242 P577 "2020-12-14T00:00:00Z" @default.
- Q104468242 P6216 Q50423863 @default.
- Q104468242 P698 "33315881" @default.
- Q104468242 P921 Q187255 @default.
- Q104468242 P932 "7735569" @default.